NK/T cell lymphoma
Conditions
Interventions
study group:Golidocitinib 150mg QD
pegaspargase 2500U/? (3750IU) D2
gemcitabine 1g/? D1,8
oxaliplatin
Sponsors
The first affiliated hospital Zhejiang University school of medicine
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1) According to the fifth edition of WHO Classification of lymphohematopoietic system tumors, the patient was pathologically diagnosed as extranodal NK/T cell lymphoma; 2) Age 18-80; 3) Newly diagnosed extranodal NK/T cell lymphoma without receiving radiotherapy or chemotherapy; 4)Ann Arbor stage III-IV, or non-upper respiratory/digestive tract ENKTL; 5)PET-CT or CT/MRI shows at least one two-dimensional measurable lesion (maximum diameter > 1.5cm); 6) Women of childbearing age must be confirmed not to be pregnant through pregnancy tests, and are willing to take effective contraceptive measures during the test period and =12 months after the last dose of medication; Pregnant and lactating women cannot participate; All male subjects used contraception during the study period and =3 months after the last dose; 7) Can provide informed consent, can understand and comply with the study.
Exclusion criteria
Exclusion criteria: 1) Have a serious mental illness; 2)HIV infection; 3) severe renal dysfunction (glomerular filtration rate 20) 5) history of other active tumors 6) pregnant or lactating women 7) failure to understand or follow the study protocol.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-free survival;safety; | — |
Secondary
| Measure | Time frame |
|---|---|
| overall response rate;complete remission rate;partial remission rate;overall survival; | — |
Countries
China
Contacts
Public ContactHongyan Tong
The first affiliated hospital Zhejiang University school of medicine
Outcome results
None listed